Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

754 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology.
Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M; ESC Committee for Practice Guidelines (CPG). Van de Werf F, et al. Eur Heart J. 2008 Dec;29(23):2909-45. doi: 10.1093/eurheartj/ehn416. Epub 2008 Nov 12. Eur Heart J. 2008. PMID: 19004841 No abstract available.
Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus.
Kereiakes DJ, Montalescot G, Antman EM, Cohen M, Darius H, Ferguson JJ, Grines C, Karsch KR, Kleiman NS, Moliterno DJ, Steg PG, Teirstein P, Van de Werf F, Wallentin L. Kereiakes DJ, et al. Among authors: van de werf f. Am Heart J. 2002 Oct;144(4):615-24. doi: 10.1067/mhj.2002.124405. Am Heart J. 2002. PMID: 12360156 Review.
Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials.
Hasdai D, Topol EJ, Kilaru R, Battler A, Harrington RA, Vahanian A, Ohman EM, Granger CB, Van de Werf F, Simoons ML, O'connor CM, Holmes DR Jr. Hasdai D, et al. Among authors: van de werf f. Am Heart J. 2003 Jan;145(1):73-9. doi: 10.1067/mhj.2003.53. Am Heart J. 2003. PMID: 12514657
Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology.
Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, Julian D, Lengyel M, Neumann FJ, Ruzyllo W, Thygesen C, Underwood SR, Vahanian A, Verheugt FW, Wijns W; Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Van de Werf F, et al. Eur Heart J. 2003 Jan;24(1):28-66. doi: 10.1016/s0195-668x(02)00618-8. Eur Heart J. 2003. PMID: 12559937 No abstract available.
One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction.
Sinnaeve P, Alexander J, Belmans A, Bogaerts K, Langer A, Diaz R, Ardissino D, Vahanian A, Pehrsson K, Armstrong P, Van de Werf F; ASSENT-2 Investigators. Sinnaeve P, et al. Among authors: van de werf f. Am Heart J. 2003 Jul;146(1):27-32. doi: 10.1016/S0002-8703(03)00117-0. Am Heart J. 2003. PMID: 12851604 Clinical Trial.
Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab.
Dubois CL, Belmans A, Granger CB, Armstrong PW, Wallentin L, Fioretti PM, López-Sendón JL, Verheugt FW, Meyer J, Van de Werf F; ASSENT-3 Investigators. Dubois CL, et al. Among authors: van de werf f. J Am Coll Cardiol. 2003 Oct 1;42(7):1178-85. doi: 10.1016/s0735-1097(03)00917-3. J Am Coll Cardiol. 2003. PMID: 14522476 Free article. Clinical Trial.
Variations in pre-hospital fibrinolysis process of care: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic 3 Plus international acute myocardial infarction pre-hospital care survey.
Welsh RC, Goldstein P, Adgey J, Verheugt F, Bestilny SA, Wallentin L, Van de Werf F, Armstrong PW; Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT) 3 Plus Trial Investigators. Welsh RC, et al. Among authors: van de werf f. Eur J Emerg Med. 2004 Jun;11(3):134-40. doi: 10.1097/01.mej.0000127653.61705.54. Eur J Emerg Med. 2004. PMID: 15167171
Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction.
Sinnaeve PR, Alexander JH, Bogaerts K, Belmans A, Wallentin L, Armstrong P, Adgey JA, Tendera M, Diaz R, Soares-Piegas L, Vahanian A, Granger CB, Van De Werf FJ. Sinnaeve PR, et al. Am Heart J. 2004 Jun;147(6):993-8. doi: 10.1016/j.ahj.2003.12.028. Am Heart J. 2004. PMID: 15199346 Clinical Trial.
Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy.
Taher T, Fu Y, Wagner GS, Goodman SG, Fresco C, Granger CB, Wallentin L, van de Werf F, Verheugt F, Armstrong PW. Taher T, et al. Among authors: van de werf f. J Am Coll Cardiol. 2004 Jul 7;44(1):38-43. doi: 10.1016/j.jacc.2004.03.041. J Am Coll Cardiol. 2004. PMID: 15234403 Free article. Clinical Trial.
754 results